Pharmacologic blockade of the renin-angiotensin system: Vascular benefits beyond commonly understood pharmacologic actions

Pharmacotherapy

Volumn 23, Issue 9 I, 2003, Pages 1141-1152

  Tsikouris, James P ^a,b   Cox, Craig D ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II [3-8]; BENAZEPRILAT; C REACTIVE PROTEIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; IMIDAPRIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINAPRIL; RAMIPRIL; REACTIVE OXYGEN METABOLITE; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; ENZYME INHIBITION; FIBRINOLYSIS; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INHIBITION KINETICS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0141791599     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.10.1141.32763     Document Type: Review

References (147)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity in survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
2. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effects of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
3. Pfefer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992;327:669-77.
4. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian enalapril survival study. N Engl J Med 1987;316:1429-35.
5. The SOLVD Investigators. The effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
6. Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine/isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
7. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
9. Luscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. Boca Raton, FL: CRC Press, 1990.
10. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.
11. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652-62.
12. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointimal formation. Circulation 1994;90:449-55.
13. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
14. 2 receptors. Kidney Int 2002;61:1986-95.
15. 1 knockout mice. Nephrol Dial Transplant 2001;16:27-33.
16. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52.
17. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001;87:C25-32.
18. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991;68:B28-35
19. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-81.
20. Falk E, Shah PK, Fuster V, et al. Coronary plaque disruption. Circulation 1995;92:657-71.
21. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-7.
22. Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987;70:1645-53.
23. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997;79:12-16.
24. Van Hinsberg VWM, Kooistra T, Emeis JJ, et al. Regulation of plasminogen activator production by endothelial cells: role in fibrinolysis and local proteolysis. Int J Radiat Biol 1991;60:261-72.
25. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990;265:109-13.
26. Thorsen S, Philips M, Selmer J, et al. Kinetics of inhibition of tissue-type plasminogen activator by plasminogen activator inhibitor type 1 and 2. Eur J Biochem 1988;175:33-9.
27. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
28. Francis RB Jr, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988;115:776-80.
29. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park heart study. Lancet 1993;342:1076-9.
30. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63.
31. Schneider DJ, Ricci MA, Taatjes DJ, et al. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol 1997;17:3294-301.
32. Tipping PG, Davenport P, Gallicchio M, Filonzi EL, Apostolopoulos J, Wojta J. Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. Am J Pathol 1993;143:875-85.
33. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998-7002.
34. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993;13:1090-100.
35. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-55.
36. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986;314:488-500.
37. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
38. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis 1984;53:265-71.
39. Ip HJ, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667-87.
40. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990;67:61-7.
41. He CS, Wilhelm SM, Pentland AP, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989;86:2632-6.
42. Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE. Arterial smooth muscle: a multifunctional mesenchymal cell. Arch Pathol Lab Med 1988;112:977-86.
43. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol 1989;14(suppl 6):S12-15.
44. Noda-Heiny H, Sobel BE. Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol 1995;268:C1105-201.
45. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the rennin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
46. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999;34:285-90.
47. Brown NJ, Gainer JV, Stein CM, et al. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999;33:1431-5.
48. Smith D, Gilbert M, Owen G. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985;66:835-9.
49. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997;77:522-5.
50. Nagata K, Ishibashi T, Sakamoto T, et al. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J Hypertens 2001;19:775-83.
51. Katoh M, Egashira K, Mitsui T, et al. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. J Cardiovasc Pharmacol 2000;35:932-6.
52. Zaman T, Fujii S, Sawa H, et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation 2001;103:3123-8.
53. Brown NJ, Agirbasli MA, Williams GH, et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-71.
54. Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442-7.
55. Jansson JH, Boman K, Nilsson TK. Enalapril-related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993;44:485-8.
56. Pederson OD, Gram J, Jeunemaitre X, et al. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Coron Artery Dis 1997;8:283-91.
57. Unger T, Ganten D, Lang RE, Scholkens BA. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe 498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985;7:36-41.
58. Lyons D, Webster J, Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373-8.
59. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-8.
60. Fabris B, Jackson B, Cubela R, Mendelsohn FA, Johnston CI. Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo. Clin Exp Pharmacol Physiol 1989;16:309-13.
61. Tsikouris JP, Suarez JA, Ziska M, Meyerrose GE. Questioning a class effect: does angiotensin-converting enzyme inhibitor tissue penetration influence markers of myocardial reinfarction risk [abstr]. Pharmacotherapy 2002;22:1326-7.
62. Weinbergen H, Schiele R, Gitt AK, et al. Impact of ramipril versus other ACE inhibitors on outcomes of unselected patients with ST-elevation acute myocardial infarction. Am J Cardiol 2002;90:1045-9.
63. Moriyama Y, Ogawa H, Oshima S, et al. Relationship between serum angiotensin converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction. Coron Artery Dis 1998;9:691-6.
64. Wright RA, Flapan AD, Alberti GMM, et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
65. Soejima H, Ogawa H, Yasue H, et al. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997;20:441-5.
66. Okamura T, Kitamura Y, Kimura T, et al. Comparison of selective actions of imidaprilat and enalaprilat on the response to angiotensin I and bradykinin in isolated dog blood vessels [in Japanese]. Oyo Yakuri/Pharmacometrics 1993;46:427-36.
67. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515-20.
68. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993;22:579-84.
69. Goodfield N, Newby DE, Ludlam CA, et al. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999;99:2983-5.
70. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999;31:61-74.
71. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001;104:1114-18.
72. Weidinger FF, McLenachan JM, Cybulsky MI, et al. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 1990;81:1667-79.
73. Shimokawa H, Aarhus LL, Vanhoutte PM. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 1987;61:256-70.
74. Inoue A, Yanagisawa M, Takuwa Y, et al. The human preproendothelin-1 gene: complete nucleotide sequence and regulation of expression. J Biol Chem 1989;264:14954-9.
75. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-7.
76. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in active constriction of human atherosclerotic coronary arteries. Circulation 2001;104:1114-18.
77. Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1001;69:209-15.
78. A receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998;31:499-504.
79. B receptor blockade. Circulation 1999;100:5-8.
80. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989;78:225-8.
81. B receptors mediate vascular smooth muscle cell contraction. Br J Pharmacol 1992;107:858-60.
82. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203-8.
83. Lin HY, Kaji EH, Winkel GK, et al. Cloning and functional expression of a vascular smooth muscle endothelin-1 receptor. Proc Natl Acad Sci USA 1991;88:3185-9.
84. Watanabe T, Suzuki N, Shimamoto, et al. Contribution of endogenous endothelins to the extension of myocardial infarction size in rats. Circ Res 1991;69:370-7.
85. Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993;88:43-54.
86. Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary artery vessels. J Am Coll Cardiol 1996;27:658-63.
87. Spieker LE, Corti R, Binggeli C, et al. Baroreceptor dysfunction induced by nitric oxide synthase inhibition in man. J Am Coll Cardiol 2000;36:213-18.
88. Brady AJB, Warren JB, Poole-Wilson PA, et al. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993;265:H176-82.
89. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
90. Weishaar RE, Panek RL, Major TC, et al. Evidence for a functional tissue renin angiotensin system in the rat mesenteric vasculature and its involvement in regulating blood pressure. J Pharmacol Exp Ther 1991;256:568-74.
91. Brown NJ, Vaughn DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000;45:419-29.
92. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium derived nitric oxide in the modulation of canine myocardial mitochondria in vitro: implications for the development of heart failure. Circ Res 1996;79:381-7.
93. Luscher TF. Endothelin: systemic arterial and pulmonary effects of a new peptide with potent biological properties. Am Rev Respir Dis 1992;146:S56-60.
94. 2 receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries. J Cardiovasc Pharmacol 2000;36:S395-6.
95. 1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998;38:631-45.
96. Kim S, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001;103:148-54.
97. Delles C, Jacobi J, John S, et al. Effect of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002;61:1462-8.
98. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type-1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease. Circulation 2001;103:799-805.
99. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-9.
100. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100:264-9.
101. Zhang X, Xie Y, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95:176-82.
102. Ross R. Mechanisms of disease: atherosclerosis, an inflammatory disease. N Engl J Med 1999;340:115-26.
103. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after onset of acute myocardial infarction. Am Heart J 2000;140:324-8.
104. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
105. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol 1998;31:1460-5.
106. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977;57:313-70.
107. Weiss D, Kools JJ, Taylor R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001;103:448-54.
108. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2001;105:1605-12.
109. Murphy TJ, Alexander RW, Griendling, et al. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991;351:233-6.
110. Owen CA, Campbell EJ. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 1998;160:1436-43.
111. Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999;100:1223-9.
112. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin converting enzyme inhibition prevents arterial nuclear factor kB activation, MCP-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
113. Agrawal A, Molstad H, Samols D, Rushner I. Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein (C/EBPb) and Rel p50. J Immunol 2001;166:2378-84.
114. Barnes PJ, Karin M. Nuclear factor-k: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
115. Han Y, Runge M, Brasier A. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kB transcription factors. Circ Res 1999;84:695-703.
116. Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 1996;5:9060-4.
117. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993;126:1299-304.
118. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
119. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first two days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99:2079-84.
120. Harris TB, Ferucci, Tracy RP. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12.
121. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2001;342:836-43.
122. Mendall MA, Strachan DP, Butland BK. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2001;21:1584-90.
123. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after onset of acute myocardial infarction. Am Heart J 2000;140:324-8.
124. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
125. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol 1998;31:1460-5.
126. Prasad A, Koh KK, Schenke WH, et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001;142:248-53.
127. Tan K, Chow W, Wong Y, Shiu S, Tam S. Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microalbuminuria. Diabetes Care 2002;25;1254.
128. Andersen S, Schalkwijk CG, Stehouwer CD, Parving H. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care 2000;23:1031-2.
129. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. II. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-38.
130. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
131. Little WC, Downes TR, Applegate RJ, et al. The underlying coronary lesion in myocardial infarction: implications for coronary angiography. Clin Cardiol 1991;14:868-74.
132. Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary artery stenosis at prior angiography. Am J Cardiol 1992;69:729-32.
133. Hackett D, Davies G, Maseri A. Pre-existing coronary stenosis in patients with first myocardial infarction are not necessarily severe. Eur Heart J 1988;9:1317-23.
134. Terrosu P, Ibba GV, Contini GM, Franceschino V. Angiographic features of the coronary arteries during intracoronary thrombolysis. Br Heart J 1984;52:154-63.
135. The Thrombolysis In Myocardial Infarction Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
136. Marshall JC, Waxman HL, Sauerwein A, Gilchrist I, Kurnik PB. Frequency of low-grade residual coronary stenosis after thrombolytis during acute myocardial infarction. Am J Cardiol 1990;66:773-8.
137. Ridolfi RL, Hutchins GM. Relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am Heart J 1977;93:468-86.
138. Kragel AH, Reddy SG, Wittes JT, Roberts WC. Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation 1989;80:1747-56.
139. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell count. Br Heart J 1993;69:377-81.
140. Burleigh MC, Briggs AD, Lendon CL, et al. Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations. Atherosclerosis 1992;96:71-81.
141. Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994;90:1669-78.
142. Constantinides P, Robinson M. Ultrastructural injury of arterial endothelium. II. Effects of vasoactive amines. Arch Pathol 1969;88:106-12.
143. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-31.
144. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15:S65-72.
145. Rolland PH, Charpiot P, Friggi A, et al. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993;71:E22-7.
146. Powell JS, Clozel JP, Muller RK, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
147. Berk BC, Vekshtein V, Gordon HM, Tsude T. Angiotensin II-stimulated protein synthesis in culture vascular smooth muscle cells. Hypertension 1989;13:305-14.